FibroGen (FGEN) Tops Q4 EPS by 21c

FibroGen (NASDAQ: FGEN) reported Q4 EPS of ($0.70), $0.21 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $34.37 million versus the consensus estimate of $24.05 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• T. Rowe Price AUM reaches $1.89 trillion at end of June 2026
• JD.com, Inc (JD) PT Lowered to $37 at Macquarie ahead of earnings